The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: aprospective cohort study: Hereditary thrombophilia and VTE in colorectal cancer surgery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10393428" target="_blank" >RIV/00064165:_____/19:10393428 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10393428 RIV/00216208:11510/19:10393428

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=bAgrLE3du1" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=bAgrLE3du1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10353-018-0534-0" target="_blank" >10.1007/s10353-018-0534-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: aprospective cohort study: Hereditary thrombophilia and VTE in colorectal cancer surgery

Popis výsledku v původním jazyce

Background: Hereditary thrombophilia may play an important role in the rate of postoperative venous thromboembolism (VTE). We focused on the impact of hereditary thrombophilia on VTE incidence in colorectal cancer surgery patients within a 1-year postoperative period. Methods: Preoperatively, identifying of colorectal cancer patients with thrombotic mutations (PTM+) and without thrombotic mutations (PTM-) was performed by screening of factor V Leiden (FVL) and prothrombin G20210A mutation. Within prophylactic period (0-28 days postoperatively), coagulation markers (platelets, fibrinogen, D-dimer) were measured and symptomatic VTE was observed. Within post-prophylactic period (2-12 months after surgery), symptomatic VTE was observed. Results: In all, 202 patients were assessed and hereditary thrombophilia was detected in 9.9% (FVL 8.4%; prothrombin G20210A mutation 1.5%). In the prophylactic period, VTE incidence in PTM+ and PTM- was 0.0% and 1.6%, respectively (p = 0.730). Levels of coagulation markers were comparable in both patient cohorts within 28 days postoperatively. In the post-prophylactic period, VTE incidence in PTM+ and PTM- was 15.0% and 5.5%, respectively (p = 0.125), and detailed incidence of deep vein thrombosis (DVT) in PTM+ and PTM- was 15.0% and 3.3%, respectively (p = 0.048). We observed significantly increased incidence of lower extremity DVT in such patients with FVL (17.6%). Conclusion: The standard regimen of extended-duration VTE prophylaxis is adequate for colorectal cancer patients with thrombotic mutations and more intensified VTE prophylaxis within the 28-day postoperative period is not justified. However, the ongoing postoperative pharmacologic prophylaxis (&gt;28 days) should be considered in patients with hereditary thrombophilia, especially with FVL.

Název v anglickém jazyce

The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: aprospective cohort study: Hereditary thrombophilia and VTE in colorectal cancer surgery

Popis výsledku anglicky

Background: Hereditary thrombophilia may play an important role in the rate of postoperative venous thromboembolism (VTE). We focused on the impact of hereditary thrombophilia on VTE incidence in colorectal cancer surgery patients within a 1-year postoperative period. Methods: Preoperatively, identifying of colorectal cancer patients with thrombotic mutations (PTM+) and without thrombotic mutations (PTM-) was performed by screening of factor V Leiden (FVL) and prothrombin G20210A mutation. Within prophylactic period (0-28 days postoperatively), coagulation markers (platelets, fibrinogen, D-dimer) were measured and symptomatic VTE was observed. Within post-prophylactic period (2-12 months after surgery), symptomatic VTE was observed. Results: In all, 202 patients were assessed and hereditary thrombophilia was detected in 9.9% (FVL 8.4%; prothrombin G20210A mutation 1.5%). In the prophylactic period, VTE incidence in PTM+ and PTM- was 0.0% and 1.6%, respectively (p = 0.730). Levels of coagulation markers were comparable in both patient cohorts within 28 days postoperatively. In the post-prophylactic period, VTE incidence in PTM+ and PTM- was 15.0% and 5.5%, respectively (p = 0.125), and detailed incidence of deep vein thrombosis (DVT) in PTM+ and PTM- was 15.0% and 3.3%, respectively (p = 0.048). We observed significantly increased incidence of lower extremity DVT in such patients with FVL (17.6%). Conclusion: The standard regimen of extended-duration VTE prophylaxis is adequate for colorectal cancer patients with thrombotic mutations and more intensified VTE prophylaxis within the 28-day postoperative period is not justified. However, the ongoing postoperative pharmacologic prophylaxis (&gt;28 days) should be considered in patients with hereditary thrombophilia, especially with FVL.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

<a href="/cs/project/NT13251" target="_blank" >NT13251: Vliv trombofilních faktorů na riziko výskytu pooperační tromboembolické nemoci (TEN) u pacientů indikovaných k plánované operaci pro karcinom v dutině břišní.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Surgery - Acta Chirurgica Austriaca

ISSN

1682-8631

e-ISSN

—

Svazek periodika

51

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

8

Strana od-do

5-12

Kód UT WoS článku

000457151800002

EID výsledku v databázi Scopus

2-s2.0-85048535020